Logo

Incogen Gets $2M from NCI for Cancer Diagnostic Software Development

Apr 19, 2004

NEW YORK, April 19 (GenomeWeb News) - Incogen said today that it has received a $2 million Phase II grant from the National Cancer Institute to develop its cancer diagnostic software.

 

The company will work with the Collegeof Williamand Mary and the EasternVirginiaMedicalSchoolon the project.

 

The two-year grant follows on a Phase I grant awarded to Incogen a year ago, which funded the development of a pilot project to analyze proteomics data produced by Ciphergen Biosystems' SELDI platform. In the second phase of the project, Incogen hopes to develop a clinical diagnostic software package for distribution to clinical researchers.

 

EVMS will produce the data for the project, while W&M and Incogen will analyze the data, the company said.

 

Breaking News
The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.